Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool.

Authors: Thwing J,Eisele TP,Steketee RW,
Address: Malaria Branch, Malaria Branch, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. jthwing@cdc.gov
Journal: BMC Public Health.


Publication: 2011 Apr 13;11 Suppl 3:S14. doi: 10.1186/1471-2458-11-S3-S14.

abstract

BACKGROUND:

the Lives Saved Tool (LiST) model was developed to estimate the impact of the scale-up of child survival interventions on child mortality. New advances in antimalarials have improved their efficacy of treating uncomplicated and severe malaria. Artemisinin-based combination therapies (ACTs) for uncomplicated Plasmodium falciparum malaria and parenteral or rectal artemisinin or quinine for severe malaria syndromes have been shown to be very effective for the treatment of malaria in children. These interventions are now being considered for inclusion in the LiST model. However, for obvious ethical reasons, their Protective efficacy (PE) compared to placebo is unknown and their impact on reducing malaria-attributable mortality has not been quantified.

METHODS:

We performed systematic literature reviews of published studies in P. falciparum endemic settings to determine the protective efficacy (PE) of ACT treatment against malaria deaths among children with uncomplicated malaria, as well as the PE of effective case management including parenteral quinine against malaria deaths among all hospitalized children. As no randomized placebo-controlled trials of malaria treatment have been conducted, we used multiple data sources to ascertain estimates of PE, including a previously performed Delphi estimate for treatment of uncomplicated malaria.

RESULTS:

Based on multiple data sources, we estimate the PE of ACT treatment of uncomplicated P. falciparum malaria on reducing malaria mortality in children 1-23 months to be 99% (range: 94-100%), and in children 24-59 months to be 97% (range: 86-99%). We estimate the PE of treatment of severe P. falciparum malaria with effective case management including intravenous quinine on reducing malaria mortality in children 1-59 months to be 82% (range: 63-94%) compared to no treatment.

CONCLUSIONS:

This systematic review quantifies the PE of ACT used for treating uncomplicated malaria and effective case management including parenteral quinine for treating severe P. falciparum malaria for preventing malaria mortality in children <5. These data will be used in the Lives Saved Tool (LiST) model for estimating the impact of scaling-up these interventions against malaria. However, in order to estimate the reduction in child mortality due to scale-up of these interventions, it is imperative to develop standardized indicators to measure population coverage of these interventions.



Related Articles
Review Protective efficacy of interventions for preventing malaria mortality in children in Plasmodium falciparum endemic areas.
Int J Epidemiol. 2010
Review Protective efficacy of interventions for preventing malaria mortality in children in Plasmodium falciparum endemic areas.
Eisele TP, Larsen D, Steketee RW. Int J Epidemiol. 2010 Apr; 39 Suppl 1:i88-101.
Review Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review.
Malar J. 2008
Review Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review.
Praygod G, de Frey A, Eisenhut M. Malar J. 2008 Oct 17; 7:210. Epub 2008 Oct 17.
Review Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies.
Curr Opin Pediatr. 2010
Review Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies.
Yeka A, Harris JC. Curr Opin Pediatr. 2010 Dec; 22(6):798-803.
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
JAMA. 2007
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ. JAMA. 2007 May 23; 297(20):2210-9.
Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria.
Malar J. 2009
Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria.
Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA, et al. Malar J. 2009 Jun 8; 8:125. Epub 2009 Jun 8.
Willingness to use a rapid diagnostic test for malaria in a rural area of central Côte d'Ivoire.
BMC Public Health. 2012
Willingness to use a rapid diagnostic test for malaria in a rural area of central Côte d'Ivoire.
Comoé CC, Ouattara AF, Raso G, Tanner M, Utzinger J, Koudou BG. BMC Public Health. 2012 Dec 18; 12:1089. Epub 2012 Dec 18.
Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001-2010.
Malar J. 2012
Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001-2010.
Eisele TP, Larsen DA, Walker N, Cibulskis RE, Yukich JO, Zikusooka CM, Steketee RW. Malar J. 2012 Mar 28; 11:93. Epub 2012 Mar 28.
Lives saved from malaria prevention in Africa--evidence to sustain cost-effective gains.
Malar J. 2012
Lives saved from malaria prevention in Africa--evidence to sustain cost-effective gains.
Korenromp EL. Malar J. 2012 Mar 28; 11:94. Epub 2012 Mar 28.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.